Literature DB >> 16840869

Normal age-related sensitivity loss for a variety of visual functions throughout the visual field.

Stuart K Gardiner1, Chris A Johnson, Paul G D Spry.   

Abstract

PURPOSE: The purpose of this study is to compare the rate of age-related decline, the magnitude of practice effects, and test-retest variability among normal subjects using six different tests of visual function.
METHODS: One hundred normal subjects aged between 20 and 85 were enrolled in the study. Six visual field test procedures were used consisting of standard automated perimetry (SAP), short wavelength automated perimetry (SWAP), temporal modulation perimetry (TMP), frequency-doubling technology perimetry (FDT), detection acuity perimetry (DAP),and resolution acuity perimetry (RAP). To facilitate direct comparison, the results for each test were divided by that test's estimated dynamic range.
RESULTS: Of the three tests used clinically most commonly, SWAP exhibited the greatest aging and practice effects and test-retest variability followed by FDT with SAP exhibiting the least. RAP was the most variable test followed by TMP.
CONCLUSIONS: These results should be taken into account when evaluating glaucomatous loss using different functional tests and when comparing the performance, predictive power, and speed of detection of the different tests.

Entities:  

Mesh:

Year:  2006        PMID: 16840869     DOI: 10.1097/01.opx.0000225108.13284.fc

Source DB:  PubMed          Journal:  Optom Vis Sci        ISSN: 1040-5488            Impact factor:   1.973


  12 in total

Review 1.  Ageing and visual field data.

Authors:  Paolo Brusini
Journal:  Br J Ophthalmol       Date:  2007-10       Impact factor: 4.638

2.  Perimetric evaluation of saccadic latency, saccadic accuracy, and visual threshold for peripheral visual stimuli in young compared with older adults.

Authors:  David E Warren; Matthew J Thurtell; Joy N Carroll; Michael Wall
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-08-27       Impact factor: 4.799

Review 3.  Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma.

Authors:  C Gustavo De Moraes; Jeffrey M Liebmann; Leonard A Levin
Journal:  Prog Retin Eye Res       Date:  2016-10-20       Impact factor: 21.198

4.  Is there evidence for continued learning over multiple years in perimetry?

Authors:  Stuart K Gardiner; Shaban Demirel; Chris A Johnson
Journal:  Optom Vis Sci       Date:  2008-11       Impact factor: 1.973

5.  Assessment of patient opinions of different clinical tests used in the management of glaucoma.

Authors:  Stuart K Gardiner; Shaban Demirel
Journal:  Ophthalmology       Date:  2008-12       Impact factor: 12.079

6.  Reduced sampling efficiency causes degraded Vernier hyperacuity with normal aging: Vernier acuity in position noise.

Authors:  Roger W Li; Brian Brown; Marion H Edwards; Charlie V Ngo; Sandy W Chat; Dennis M Levi
Journal:  Sci Rep       Date:  2012-03-05       Impact factor: 4.379

7.  Diagnostic Ability and Repeatability of a New Supra-Threshold Glaucoma Screening Program in Standard Automated Perimetry.

Authors:  Natsumi Takahashi; Kazunori Hirasawa; Miki Hoshina; Masayuki Kasahara; Kazuhiro Matsumura; Nobuyuki Shoji
Journal:  Transl Vis Sci Technol       Date:  2017-05-22       Impact factor: 3.283

8.  Aging of low and high level vision: from chromatic and achromatic contrast sensitivity to local and 3D object motion perception.

Authors:  Catarina Mateus; Raquel Lemos; Maria Fátima Silva; Aldina Reis; Pedro Fonseca; Bárbara Oliveiros; Miguel Castelo-Branco
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

Review 9.  Teleglaucoma: ready to go?

Authors:  N G Strouthidis; G Chandrasekharan; J P Diamond; I E Murdoch
Journal:  Br J Ophthalmol       Date:  2014-04-10       Impact factor: 4.638

10.  Impact of Age and Myopia on the Rate of Visual Field Progression in Glaucoma Patients.

Authors:  Hae-Young Lopilly Park; Kyung Euy Hong; Chan Kee Park
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.